Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Gallo

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
Pharmaceutical Statistics|November 4, 2006
Operational challenges in adaptive design implementationPaul Gallo
Biometrical Journal. Biometrische Zeitschrift|September 16, 2006
Challenges in implementing adaptive designs: comments on the viewpoints expressed by regulatory statisticiansPaul Gallo, Willi Maurer
Therapeutic Innovation & Regulatory Science|February 3, 2023
Challenges in Implementing Futility Schemes, with Reference to AducanumabPaul Gallo, Satrajit Roychoudhury
Statistics in Medicine|July 25, 2019
An additive boundary for group sequential designs with connection to conditional errorDong Xi, Paul Gallo
Pharmaceutical Statistics|July 22, 2008
What should be the role of homogeneity testing in adaptive trials?Paul Gallo, Christy Chuang-Stein
Therapeutic Innovation & Regulatory Science|September 21, 2018
Adaptive Clinical Trials: Overview of Phase III Designs and ChallengesJeff Maca, Vladimir Dragalin, Paul Gallo
Clinical Trials (London, England)|October 7, 2017
Adaptive designs: The Swiss Army knife among clinical trial designs?Frank Bretz, Paul Gallo, Willi Maurer
Immunology Letters|July 31, 2010
The influence of IgG density and macrophage Fc (gamma) receptor cross-linking on phagocytosis and IL-10 productionPaul Gallo, Ricardo Gonçalves, David M Mosser
Journal of Biopharmaceutical Statistics|June 17, 2014
Alternative views on setting clinical trial futility criteriaPaul Gallo, Lu Mao, Vivian H Shih
Cost Effectiveness and Resource Allocation : C/E|March 19, 2013
Modeling the indirect economic implications of musculoskeletal disorders and treatmentTimothy M Dall, Paul Gallo, Lane Koenig, et al.
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
Pharmaceutical Statistics|November 4, 2006
Operational challenges in adaptive design implementationPaul Gallo
Biometrical Journal. Biometrische Zeitschrift|September 16, 2006
Challenges in implementing adaptive designs: comments on the viewpoints expressed by regulatory statisticiansPaul Gallo, Willi Maurer
Therapeutic Innovation & Regulatory Science|February 3, 2023
Challenges in Implementing Futility Schemes, with Reference to AducanumabPaul Gallo, Satrajit Roychoudhury
Statistics in Medicine|July 25, 2019
An additive boundary for group sequential designs with connection to conditional errorDong Xi, Paul Gallo
Pharmaceutical Statistics|July 22, 2008
What should be the role of homogeneity testing in adaptive trials?Paul Gallo, Christy Chuang-Stein
Therapeutic Innovation & Regulatory Science|September 21, 2018
Adaptive Clinical Trials: Overview of Phase III Designs and ChallengesJeff Maca, Vladimir Dragalin, Paul Gallo
Clinical Trials (London, England)|October 7, 2017
Adaptive designs: The Swiss Army knife among clinical trial designs?Frank Bretz, Paul Gallo, Willi Maurer
Immunology Letters|July 31, 2010
The influence of IgG density and macrophage Fc (gamma) receptor cross-linking on phagocytosis and IL-10 productionPaul Gallo, Ricardo Gonçalves, David M Mosser
Journal of Biopharmaceutical Statistics|June 17, 2014
Alternative views on setting clinical trial futility criteriaPaul Gallo, Lu Mao, Vivian H Shih
Cost Effectiveness and Resource Allocation : C/E|March 19, 2013
Modeling the indirect economic implications of musculoskeletal disorders and treatmentTimothy M Dall, Paul Gallo, Lane Koenig, et al.
Pageof 4